Apomorphine is an erectile dysfunction treatment that works in the brain rather than directly on the penis, setting it apart from the more familiar PDE5 inhibitors like sildenafil and tadalafil. Taken as a small tablet that dissolves under the tongue, it activates dopamine pathways in the hypothalamus to trigger the body’s natural erection process, typically within about 20 minutes. The drug has been approved in parts of Europe under the brand name Uprima but never gained the commercial traction of its peripheral-acting competitors, despite a favorable safety profile that makes it a genuine option for certain men.
How Apomorphine Works in the Brain
Despite the name, apomorphine has nothing to do with morphine. It is a dopamine agonist, meaning it mimics the neurotransmitter dopamine at receptor sites in the brain. Its primary target is a cluster of neurons called the paraventricular nucleus, located in the hypothalamus, a brain region that serves as one of the central command centers for penile erection.1PubMed. Oral treatment of erectile dysfunction with apomorphine SL When apomorphine binds to dopamine D2 receptors in this area, it promotes the same cascade of nerve signals that occurs during natural arousal, sending erectogenic impulses down through the spinal cord and into the pelvic nerves that control blood flow to the penis.2European Urology Supplements. Apomorphine SL: Evolution of a Centrally Acting Treatment for Erectile Dysfunction
This central mechanism is fundamentally different from what PDE5 inhibitors do. Sildenafil and its relatives work at the endpoint, relaxing smooth muscle in penile blood vessels so that more blood can flow in. Apomorphine works upstream, amplifying the brain’s own arousal signals. Animal research has helped clarify one key link in this chain: dopamine activity in the paraventricular nucleus recruits an oxytocin-releasing pathway that runs from the hypothalamus down to the spinal cord, and blocking oxytocin receptors at the spinal level reduces the erectile response to apomorphine.3PubMed. Dopamine-oxytocin interactions in penile erection In other words, apomorphine doesn’t just flip a dopamine switch; it sets off a relay involving multiple chemical messengers that converge on the same outcome.
How You Take It
Apomorphine for ED comes as a sublingual tablet, meaning you place it under your tongue and let it dissolve rather than swallowing it. This is not just a convenience choice. Because the drug is absorbed through the mucous membrane under the tongue, it bypasses the digestive system and the liver’s first-pass metabolism. That means food in your stomach does not slow it down, and it avoids significant interactions with other drugs being processed through the gut.4PubMed. Sublingual apomorphine for the treatment of erectile dysfunction The tablet dissolves quickly, and in men who respond to the drug, erections typically begin within about 20 minutes.
The standard doses studied in clinical trials have been 2 mg and 3 mg. Most prescribing protocols recommend starting at the lower dose and increasing to 3 mg if needed. A dose-optimization approach, where you start low and titrate up, has been shown to reduce the already-low rates of side effects like fainting.5European Urology Supplements. Adverse Events and Patient Tolerability of Apomorphine SL 2 and 3 mg: A Cross-Study Analysis of Phase II and III Studies
How Effective Is It?
The honest answer here depends on whom you are talking about and what “effective” means. In men with milder, often psychogenic erectile dysfunction, the results are reasonably encouraging. Early clinical work found that about two-thirds of men with primarily psychogenic ED developed erections after taking a 3 or 4 mg controlled-absorption tablet, and about the same proportion found it useful in home use.6Urology. Recovery of erectile function by the oral administration of apomorphine
Larger pooled analyses paint a somewhat more nuanced picture. In optimized patient populations, roughly seven out of ten men who respond to the drug achieve an erection within 20 minutes, and that response holds up regardless of whether the underlying ED is classified as mild, moderate, or severe. Among long-term users who continued therapy, more than nine out of ten attempts were reported as successful over 18 months, with fewer than about one in seven patients experiencing side effects.7International Journal of Impotence Research. Characterising the benefit of apomorphine SL (Uprima®) as an optimised treatment for representative populations with erectile dysfunction That “who respond to therapy” qualifier matters. Not every man responds, and the clinical trials generally reported lower initial response rates before nonresponders were filtered out.
One interesting wrinkle emerged in a study that tested daily dosing rather than on-demand use. When men took apomorphine only as needed, only about one in six responded. But when the nonresponders from that group switched to taking the drug daily for four weeks, a striking majority reported satisfaction with the treatment.8PubMed. Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia This was a small pilot study, so the numbers should be treated cautiously, but it raises the possibility that for some men a daily regimen primes the dopamine pathway more effectively than sporadic doses.
What to Expect in Terms of Side Effects
The side-effect profile of sublingual apomorphine at ED doses is mild compared with both the higher doses used in Parkinson’s disease and the typical concerns around PDE5 inhibitors. The most commonly reported effects are nausea, dizziness, and headache.9PubMed. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates Nausea was especially prominent in earlier formulations; one of the first sublingual liquid preparations produced significant nausea in most patients, which drove the development of the slower-dissolving controlled-absorption tablets used in later trials.6Urology. Recovery of erectile function by the oral administration of apomorphine
The side effect that drew the most clinical scrutiny is syncope, a brief fainting episode caused by a sudden drop in blood pressure. Across pooled phase II and III data at the 2 and 3 mg doses, syncope occurred in about one in a thousand patients when a dose-optimization approach was used. No deaths, strokes, heart attacks, priapism, or inappropriate erections were linked to the drug at any dose.5European Urology Supplements. Adverse Events and Patient Tolerability of Apomorphine SL 2 and 3 mg: A Cross-Study Analysis of Phase II and III Studies Yawning is another quirk that shows up in the literature, a direct consequence of dopamine stimulation in the brain. It is harmless but can feel strange in a sexual context.
Data from Parkinson’s disease studies, where apomorphine is given at much higher and more frequent doses, confirms that adverse events increase with dose. In that population, nausea, vomiting, drowsiness, and yawning are all more common compared with placebo.10PubMed Central. Efficacy and safety of apomorphine in the treatment of Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials At the much lower ED doses, these effects are considerably less frequent, which is part of why the drug’s safety profile at 2 to 3 mg has generally been regarded as benign.
Cardiovascular Safety and Nitrate Use
One practical advantage of apomorphine over PDE5 inhibitors is its interaction profile with heart medications. Sildenafil is famously contraindicated with nitrates because the combination can cause dangerous drops in blood pressure. Apomorphine’s story is more forgiving. In a controlled study of men taking stable doses of common blood pressure medications or nitrates, sublingual apomorphine at higher-than-recommended doses produced no clinically significant changes in heart rate or blood pressure beyond what the drug caused on its own.9PubMed. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates
There were a few exceptions worth noting. Men on alpha-blockers experienced a somewhat larger drop in systolic blood pressure when standing, and those on long-acting nitrates also showed statistically significant (though small) decreases in blood pressure upon standing. A couple of patients on nitrates developed symptomatic low blood pressure, and one patient taking a beta-blocker fainted. But across the study groups, the overall conclusion was that apomorphine was safe to combine with the cardiovascular drugs that most ED patients are already taking. For men who cannot use PDE5 inhibitors because they rely on nitrates for angina, apomorphine represents one of the few oral alternatives, though careful medical supervision is still warranted given the small risk of orthostatic symptoms.
When Apomorphine Doesn’t Work Well
Because apomorphine works by amplifying brain signals rather than directly increasing penile blood flow, its effectiveness drops when the problem lies in the peripheral nervous system or the blood vessels themselves. Diabetes is a prime example. In a placebo-controlled trial of men with diabetes-related ED, only about one in five responded to apomorphine, a figure that was not statistically different from the placebo response rate. Younger men and those with better blood-sugar control were more likely to benefit, suggesting that advanced vascular or nerve damage limits the drug’s reach.11International Journal of Impotence Research. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men
A similar pattern emerged in men with spinal cord injuries. In a small study, some patients experienced partial erections, but only two achieved erections firm enough for intercourse and chose to continue the treatment.12PubMed. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury When the spinal pathways that relay signals from the brain to the pelvis are physically disrupted, a drug that boosts the brain’s output cannot fully compensate. The drug’s central mechanism is its greatest distinction but also its fundamental limitation: it works best when the wiring between brain and body is intact and the problem sits closer to the signaling side than the plumbing side.
Combining Apomorphine with Sildenafil
Because apomorphine and PDE5 inhibitors work through completely separate pathways, combining them is a logical idea, and the limited data so far looks promising. In a study comparing sildenafil alone against sildenafil plus apomorphine, the combination produced notably better results across multiple measures. The percentage of attempts resulting in erections firm enough for intercourse rose from about 63% with sildenafil alone to about 78% with the combination. Successful intercourse rates climbed from roughly a third to about half, and erectile function scores improved more with the pair than with sildenafil solo. By the end of the study, nearly nine out of ten participants preferred the combination.13Value in Health. Value in Health
This makes pharmacological sense. Sildenafil keeps the peripheral blood-flow mechanism running more efficiently, while apomorphine strengthens the initial signal from the brain. You are boosting both ends of the chain. For men who get a partial response from a PDE5 inhibitor alone, adding apomorphine could push them over the threshold to a satisfactory erection. That said, combination therapy also means combining side-effect profiles, so any such regimen should involve a physician who can weigh the cardiovascular picture.
The Role of Sexual Arousal
A common misunderstanding about apomorphine is that it creates erections on demand the way an injection into the penis might. It does not. The drug works by enhancing the brain’s natural response to sexual stimulation, not by generating arousal from scratch. Brain imaging studies have helped demonstrate this. When men with ED were given apomorphine and then shown sexually stimulating visual content, the drug increased activity in the right prefrontal cortex, a region linked to sexual arousal and orgasm in earlier research. That increased brain activity was directly associated with greater penile rigidity.14PubMed. Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction
This means you should not expect the pill to work if you take it and then sit down to read the news. The drug amplifies a process that needs to already be in motion. For some men, this is actually an advantage over injection therapies or very high doses of PDE5 inhibitors, which can sometimes produce erections at socially inconvenient moments. Research across clinical trials noted that apomorphine did not alter sexual desire itself, only the body’s ability to respond when desire was present.15International Journal of Impotence Research. Apomorphine SL (Uprima®): preclinical and clinical experiences learned from the first central nervous system-acting ED drug Partners in clinical trials reported experiences that were consistent with what the patients themselves described, suggesting the improvements were perceptible to both parties and not just a placebo-driven self-report effect.16PubMed. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
Nasal Spray and Alternative Delivery Routes
The sublingual tablet is the best-known formulation, but researchers have also explored delivering apomorphine through the nose. The logic here is compelling: the nasal cavity offers a more direct route to the brain via the olfactory nerve pathway, potentially allowing lower doses with fewer systemic side effects. Pharmacokinetic studies confirmed this. Intranasal apomorphine reached brain tissue at concentrations comparable to those achieved by subcutaneous injection, while producing only about half the drug levels in the bloodstream. Brain onset was actually faster through the nose than by injection, and roughly a third to half of the drug that reached the brain appeared to travel there directly through the olfactory pathway rather than through the blood.17PubMed. Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride
Clinical studies of the nasal spray found it was well tolerated, with lower doses needed and fewer side effects than the sublingual version. The nasal route essentially concentrates the drug where you want it (the brain) while keeping blood levels lower, which is exactly the profile you would design if you were trying to minimize nausea and dizziness while preserving the erectogenic effect. Whether a nasal formulation will ever become widely available for ED is uncertain, but the science behind it is solid and represents a logical evolution of the delivery method.
A Drug with a Complicated History
Apomorphine has had one of the stranger careers in pharmacology. It was first synthesized in the 19th century, and its uses over the decades have included inducing vomiting (its original clinical niche), treating alcoholism through aversion therapy, sedation for mental health conditions, and, most prominently today, managing motor fluctuations in Parkinson’s disease, where it is given by subcutaneous injection at much higher doses than those used for ED.18PubMed Central. The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future Its use as an erectogenic agent was identified along the way, and the sublingual formulation was specifically developed to exploit its pro-erectile properties at low doses while avoiding the nausea that comes with higher exposures.
Despite European approval, apomorphine never gained wide traction in the ED market. It arrived during the era of sildenafil’s dominance, and its lower efficacy in severe or organic ED made it a hard sell against a drug that worked for a broader range of patients. Commercial pressures, not safety failures, are what sidelined it. The drug remains available in some markets and continues to attract research interest, particularly as a combination partner for PDE5 inhibitors and as a candidate for improved nasal delivery. For men with mild to moderate ED, especially those with a significant psychogenic component or those who cannot take PDE5 inhibitors because of nitrate use, apomorphine still occupies a genuine clinical niche that no other oral drug quite fills.